FDA approves Genentech’s Vabysmo to treat two causes of vision loss

seekingalpha2022-01-31

Genentech, a member of the Roche Group (OTCQX:RHHBY) announces that the FDA has approved Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

dahae
2022-01-31
dahae
Q
rachellll
2022-01-31
rachellll
Q
Otahman
2022-01-31
Otahman
Like pls
WLtan
2022-01-31
WLtan
Great
Xalier
2022-01-31
Xalier
Like
J1000
2022-01-31
J1000
K

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2207385397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-31 16:20","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2207385397","market":"us","top_or_hot":-1,"title":"FDA approves Genentech’s Vabysmo to treat two causes of vision loss","media":"seekingalpha","content":"<div>\n<p>Genentech, a member of the Roche Group (OTCQX:RHHBY) announces that the FDA has approved Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793344-fda-approves-genentechs-vabysmo-to-treat-two-causes-of-vision-loss\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Genentech’s Vabysmo to treat two causes of vision loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Genentech’s Vabysmo to treat two causes of vision loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-31 16:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793344-fda-approves-genentechs-vabysmo-to-treat-two-causes-of-vision-loss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Genentech, a member of the Roche Group (OTCQX:RHHBY) announces that the FDA has approved Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793344-fda-approves-genentechs-vabysmo-to-treat-two-causes-of-vision-loss\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4512","symbol_name":"苹果概念","start_time":0,"source_url":"https://seekingalpha.com/news/3793344-fda-approves-genentechs-vabysmo-to-treat-two-causes-of-vision-loss","article_id":"2207385397","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2207385397","pubTimestamp":1643617200,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Genentech, a member of the Roche Group (OTCQX:RHHBY) announces that the FDA has approved Vabysmo (fa","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4512":"苹果概念","BK4141":"半导体产品","BK4554":"元宇宙及AR概念","BK4007":"制药","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","RHHBY":"罗氏控股","BK4529":"IDC概念","BK4534":"瑞士信贷持仓"},"translate_title":"FDA批准基因泰克的Vabysmo治疗两种导致视力下降的原因","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.6},"content_text":"Genentech, a member of the Roche Group (OTCQX:RHHBY) announces that the FDA has approved Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).The approval is based on positive results across four Phase III studies in wet AMD and DME. The studies consistently showed that patients treated with Vabysmo given at intervals of up to four months achieved non-inferior vision gains versus aflibercept given every two months in the first year. Vabysmo was generally well tolerated in all four studies, with a favorable benefit-risk profile.Vabysmo will be available in U.S. in the coming weeks. The EMA is also currently evaluating the Vabysmo Marketing Authorization Application for wet AMD and DME.Vabysmo is the first and only FDA-approved injectable eye medicine for wet AMD and DME that improves and maintains vision with treatments from one to four months apart in the first year following four initial monthly doses.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9093646350,"gmtCreate":1643622539901,"gmtModify":1676533837209,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3560092322694803","idStr":"3560092322694803"},"htmlText":"Q","listText":"Q","text":"Q","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093646350","repostId":2207385397,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093648476,"gmtCreate":1643622432603,"gmtModify":1676533837193,"author":{"id":"3586435391928672","authorId":"3586435391928672","name":"rachellll","avatar":"https://static.tigerbbs.com/7855a29f75174783f11b5102e8a7c8ba","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3586435391928672","idStr":"3586435391928672"},"htmlText":"Q","listText":"Q","text":"Q","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093648476","repostId":2207385397,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093657740,"gmtCreate":1643621385700,"gmtModify":1676533836894,"author":{"id":"3567482716620513","authorId":"3567482716620513","name":"Otahman","avatar":"https://static.tigerbbs.com/dbd099972f177a5bb9c4f8a5666b4a77","vip":1,"crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3567482716620513","idStr":"3567482716620513"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093657740","repostId":2207385397,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093654806,"gmtCreate":1643621003128,"gmtModify":1676533836866,"author":{"id":"3581912064711553","authorId":"3581912064711553","name":"WLtan","avatar":"https://static.tigerbbs.com/354ffef504de8ee7159ec0ecd8769350","vip":1,"crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"3581912064711553","idStr":"3581912064711553"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093654806","repostId":2207385397,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093655258,"gmtCreate":1643620759132,"gmtModify":1676533836839,"author":{"id":"3569445806394527","authorId":"3569445806394527","name":"Xalier","avatar":"https://static.tigerbbs.com/24f0858187f1785be0f6b9d132363a84","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1,"authorIdStr":"3569445806394527","idStr":"3569445806394527"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093655258","repostId":2207385397,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093656102,"gmtCreate":1643620430313,"gmtModify":1676533836760,"author":{"id":"3563859164285775","authorId":"3563859164285775","name":"J1000","avatar":"https://community-static.tradeup.com/news/b8ecd9c9f9155b597bf186803ea57192","vip":1,"crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3563859164285775","idStr":"3563859164285775"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093656102","repostId":2207385397,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":61,"commentSize":12,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2207385397"}